By Daniella Parra March Biosciences was granted an orphan drug designation from the FDA to MB-105, its CD5-targeted CAR-T ...
Company prepares to advance to Phase 2 clinical trial in early 2025HOUSTON, Jan. 28, 2025 (GLOBE NEWSWIRE) -- March Biosciences (March Bio), an ...
Biosciences receives US FDA orphan drug designation for MB-105 to treat relapsed/refractory CD5-positive T-cell lymphoma: Houston Thursday, January 30, 2025, 17:00 Hrs [IST] ...
MB-105, a first-in-class CD5-targeted CAR T-cell therapy, received FDA orphan drug designation for relapsed/refractory T-cell ...
NEW YORK CITY, NY / ACCESS Newswire / January 29, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm ...
Fintel reports that on January 23, 2025, Piper Sandler initiated coverage of Bright Minds Biosciences (NasdaqCM:DRUG) with a ...
Colossal Biosciences, the biotech company behind plans to try to bring back the woolly mammoth, Tasmanian tiger and the dodo, ...
IGM Biosciences is laying off 100 workers as it shuts down two research projects, causing the Mountain View company's stock ...
January 14, 2025--(BUSINESS WIRE)--Valent BioSciences in partnership with Meister ... by someone else at BiostimulantInnovator.com through March 12, 2025. "Valent BioSciences is looking forward ...
Fresh layoffs have jolted the Bay Area, staffing reductions that are poised to eliminate about 600 jobs in the retail, grocery, tech, biotech, and food manufacturing industries, official state labor ...